Physician profile
Paul Fu
NPI 1225440688
$4,514.67
in general payments reported to CMS, 2019-2025
26 companies · $25.71 in 2025
The $25.71 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,030 · 2021: $1,759 · 2022: $1,661 · 2023: $39.73 · 2025: $25.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,732.05 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $408.36 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $308.45 | 2020-2021 | |
| Lilly USA, LLC | $271.61 | 2020-2021 | |
| Abbvie INC. | $269.89 | 2021 | |
| Emd Serono, INC. | $180.42 | 2020-2021 | |
| Biogen, INC. | $158.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $143.42 | 2020-2021 | |
| Sk Life Science, INC. | $127.25 | 2020-2021 | |
| Celgene Corporation | $123.00 | 2020-2021 | |
| Amgen INC. | $100.48 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $83.44 | 2021 | |
| Genzyme Corporation | $83.35 | 2020 | |
| Ucb, INC. | $80.27 | 2021 | |
| Upsher-Smith Laboratories LLC | $76.64 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $63.79 | 2021-2022 | |
| Allergan, INC. | $56.04 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.92 | 2022-2023 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $45.07 | 2020 | |
| Mdd US Operations, LLC | $31.85 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.37 | 2020 | |
| Genentech USA, INC. | $26.39 | 2021 | |
| Stryker Corporation | $25.71 | 2025 | |
| Kyowa Kirin, INC. | $15.60 | 2021 | |
| Abbott Laboratories | $13.99 | 2023 | Freestyle Libre 2 |
| Neurocrine Biosciences, INC. | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.